Treace Medical Concepts, Inc. (TMCI)

Treace Medical Concepts, Inc. (TMCI) — VMCI valuation read

Headline read on TMCI: VMCI of 43/100 versus a Healthcare sector median of 50. The 7-point below-median position is what makes Treace Medical Concepts, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on TMCI: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on TMCI: value (TMCI trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -1.5x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

TMCI rose 0.2% over the trailing 7 days, with a -5.4% read on a 30-day basis.